Tectonic Therapeutic, Inc. (TECX) Dividend History

Tectonic Therapeutic, Inc. (TECX) is a biotechnology company focused on developing innovative therapies for neurological and psychiatric disorders. It aims to capitalize on its proprietary drug discovery platform to identify and develop novel compounds that address unmet medical needs in areas such as neurodegeneration and mental health conditions.

490 Arsenal Way, Watertown, MA, 02472
Phone: (339) 666-3320
Website: https://www.tectonictx.com

Dividend History

Tectonic Therapeutic, Inc. currently does not pay dividends

Company News

Tectonic (TECX) Q2 R&D Soars 142%

Biotechnology company Tectonic Therapeutic reported a wider Q2 2025 net loss of $20.0 million, driven by increased clinical trial activities for its lead drug TX45 targeting pulmonary hypertension. Despite higher expenses, the company maintains a strong cash position of $287.4 million, with runway projected into Q4 2028.

The Motley Fool
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Tectonic Therapeutic announced positive results from a Phase 1b clinical trial of its lead asset TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The data confirmed TX45's tolerability and showed improvements in left ventricular function and pulmonary hemodynamics.

GlobeNewswire Inc.

Page data last updated 08/19/2025 16:47:20 UTC